Search details
1.
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
Lancet
; 403(10441): 2293-2306, 2024 May 25.
Article
in English
| MEDLINE | ID: mdl-38705160
2.
Clinical Impact of Polymerase Chain Reaction-Based Aspergillus and Azole Resistance Detection in Invasive Aspergillosis: A Prospective Multicenter Study.
Clin Infect Dis
; 77(1): 38-45, 2023 07 05.
Article
in English
| MEDLINE | ID: mdl-36905147
3.
MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma.
J Neurooncol
; 152(2): 357-362, 2021 Apr.
Article
in English
| MEDLINE | ID: mdl-33611761
4.
Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
Br J Haematol
; 190(3): 385-393, 2020 08.
Article
in English
| MEDLINE | ID: mdl-32150297
5.
Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia.
Ann Hematol
; 99(5): 1081-1091, 2020 May.
Article
in English
| MEDLINE | ID: mdl-32193628
6.
The Role of Rituximab in Primary Central Nervous System Lymphoma.
Curr Oncol Rep
; 22(8): 78, 2020 06 29.
Article
in English
| MEDLINE | ID: mdl-32602069
7.
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Lancet Oncol
; 20(2): 216-228, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30630772
8.
Rituximab-PECC induction followed by 90 Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study.
Br J Haematol
; 187(3): 347-355, 2019 11.
Article
in English
| MEDLINE | ID: mdl-31290569
9.
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Lancet
; 391(10121): 659-667, 2018 02 17.
Article
in English
| MEDLINE | ID: mdl-29241979
10.
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.
Haematologica
; 109(1): 343-350, 2024 Jan 01.
Article
in English
| MEDLINE | ID: mdl-37470152
11.
Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.
Haematologica
; 104(1): 147-154, 2019 01.
Article
in English
| MEDLINE | ID: mdl-30115656
12.
Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis.
Hematol Oncol
; 37(5): 548-557, 2019 Dec.
Article
in English
| MEDLINE | ID: mdl-31418878
13.
Converting cyclosporine A from intravenous to oral administration in hematopoietic stem cell transplant recipients and the role of azole antifungals.
Eur J Clin Pharmacol
; 74(6): 767-773, 2018 Jun.
Article
in English
| MEDLINE | ID: mdl-29500599
14.
The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole-resistance. A nationwide survey and rationale for the DB-MSG 002 study protocol.
Mycoses
; 61(9): 656-664, 2018 Sep.
Article
in English
| MEDLINE | ID: mdl-29687483
15.
Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.
Hematol Oncol
; 35(4): 497-503, 2017 Dec.
Article
in English
| MEDLINE | ID: mdl-27530779
16.
Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.
Blood
; 123(21): 3255-62, 2014 May 22.
Article
in English
| MEDLINE | ID: mdl-24735962
17.
Primary therapy and survival in patients aged over 70-years-old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands.
Haematologica
; 106(2): 597-600, 2021 02 01.
Article
in English
| MEDLINE | ID: mdl-32241841
18.
A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib.
Eur J Clin Pharmacol
; 72(6): 719-23, 2016 Jun.
Article
in English
| MEDLINE | ID: mdl-26965514
19.
The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands.
Br J Haematol
; 188(6): e109-e112, 2020 03.
Article
in English
| MEDLINE | ID: mdl-31991479
20.
Survival continues to increase in chronic lymphocytic leukaemia: a population-based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016.
Br J Haematol
; 189(3): 574-577, 2020 05.
Article
in English
| MEDLINE | ID: mdl-31958141